Amber C. Donahue

1.3k citations

22 papers · 583 indexed · h-index 14

Co-authors: David A. Fruman Ian Magrath Eric Sariban Chen-Hsiung Yeh Jay G. Wohlgemuth Gregory Z. Ferl Owen N. Witte Anne B. Satterthwaite
Topics: Chronic Lymphocytic Leukemia Research (8 papers)Acute Myeloid Leukemia Research (5 papers)PI3K/AKT/mTOR signaling in cancer (4 papers)
Cited by: Genetics Immunology Hematology
Journals: Proceedings of the National Academy of Sciences Journal of Clinical Oncology The Journal of Immunology
Partner nations: United States United Kingdom Japan

In The Last Decade

Amber C. Donahue

22 papers receiving 568 citations

Peers

Countries citing papers authored by Amber C. Donahue

Since Specialization

Citations

This map shows the geographic impact of Amber C. Donahue's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amber C. Donahue with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amber C. Donahue more than expected).

Fields of papers citing papers by Amber C. Donahue

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amber C. Donahue. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amber C. Donahue. The network helps show where Amber C. Donahue may publish in the future.

Co-authorship network of co-authors of Amber C. Donahue

This figure shows the co-authorship network connecting the top 25 collaborators of Amber C. Donahue. A scholar is included among the top collaborators of Amber C. Donahue based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amber C. Donahue. Amber C. Donahue is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Abstract 2899: PARG inhibition provokes a DNA damage-dependent innate immune reaction that enhances ICI-driven anti-tumor immunity 2025 ·Cancer Research ·(unknown),(unknown),Pei Xin Lim,Amber C. Donahue,(unknown),Vidhya Nagarajan,(unknown),(unknown),(unknown),(unknown),(unknown),Kelly S. Trego,John L. Ryan,Kwong Wai Choy,Peter Teriete,Christian Frey,(unknown),Paul A. Barsanti,Brett A. Neilan,(unknown),Diana M. Muñoz	1
2	Integrative Analyses of Tumor and Peripheral Biomarkers in the Treatment of Advanced Renal Cell Carcinoma 2023 ·Cancer Discovery ·Toni K. Choueiri,Amber C. Donahue,David A. Braun,Brian I. Rini,Thomas Powles,John B.A.G. Haanen,James Larkin,Xinmeng Jasmine Mu,Jie Pu,Rosemary E. Teresi,(unknown),Paul B. Robbins,Robert J. Motzer	6
3	225 Avelumab alone in platinum-resistant/refractory ovarian cancer: selected biomarker analyses from the JAVELIN Ovarian 200 trial 2021 ·Éric Pujade-Lauraine,Jonathan A. Ledermann,Amit M. Oza,Rebecca Kristeleit,Isabelle Ray‐Coquard,Gary Richardson,Cristiana Sessa,Kan Yonemori,Susana Banerjee,Alexandra Léary,Xinmeng Jasmine Mu,Y Liu,Keith A. Ching,Shibing Deng,Julia Perkins Smith,Amber C. Donahue,Keiichi Fujiwara,Bradley J. Monk	1
4	229 Avelumab combined with pegylated liposomal doxorubicin in platinum-resistant/refractory ovarian cancer: biomarker analyses from JAVELIN Ovarian 200 2021 ·Éric Pujade-Lauraine,Jonathan A. Ledermann,Amit M. Oza,Rebecca Kristeleit,Isabelle Ray‐Coquard,Gary Richardson,Cristiana Sessa,Kan Yonemori,Susana Banerjee,Alexandra Léary,Xinmeng Jasmine Mu,Y Liu,Keith A. Ching,Shibing Deng,Julia Perkins Smith,Amber C. Donahue,Keiichi Fujiwara,Bradley J. Monk	1
5	Integrating peripheral biomarker analyses from JAVELIN Renal 101: Avelumab + axitinib (A + Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC). 2021 ·Journal of Clinical Oncology ·Toni K. Choueiri,Amber C. Donahue,Brian I. Rini,Thomas Powles,John B.A.G. Haanen,James Larkin,Xinmeng Jasmine Mu,Jie Pu,Despina Thomaidou,Alessandra di Pietro,Paul B. Robbins,Robert J. Motzer	1
6	Multiplex ligation-dependent probe amplification for detection of chromosomal abnormalities in myelodysplastic syndrome and acute myeloid leukemia 2011 ·Leukemia Research ·Amber C. Donahue,(unknown),(unknown),Jay G. Wohlgemuth,Chen-Hsiung Yeh	16
7	Significant association between polymorphism of the erythropoietin gene promoter and myelodysplastic syndrome 2010 ·BMC Medical Genetics ·Wanlong Ma,Hagop M. Kantarjian,Ke Zhang,Xi Zhang,Xiuqiang Wang,(unknown),Amber C. Donahue,Zhong Zhang,Chen-Hsiung Yeh,Susan O’Brien,Guillermo Garcia‐Manero,Neil E. Caporaso,Ola Landgren,Maher Albitar	15
8	Circulating Ki-67 index in plasma as a biomarker and prognostic indicator in chronic lymphocytic leukemia 2010 ·Leukemia Research ·Jean-Marie Bruey,Hagop M. Kantarjian,Wanlong Ma,Zeev Estrov,Chen-Hsiung Yeh,Amber C. Donahue,Heather Sanders,Susan O’Brien,Michael J. Keating,Maher Albitar	11
9	Detection, Analysis and Clinical Validation of Chromosomal Aberrations by Multiplex Ligation-Dependent Probe Amplification in Chronic Leukemia 2010 ·PLoS ONE ·(unknown),Amber C. Donahue,Jay G. Wohlgemuth,Chen-Hsiung Yeh	26
10	Proteasome Enzymatic Activities in Plasma as Risk Stratification of Patients with Acute Myeloid Leukemia and Advanced-Stage Myelodysplastic Syndrome 2009 ·Clinical Cancer Research ·Wanlong Ma,Hagop M. Kantarjian,B. Nebiyou Bekele,Amber C. Donahue,Xi Zhang,(unknown),Susan O’Brien,Elihu H. Estey,Zeev Estrov,Jörge E. Cortes,Michael J. Keating,Francis J. Giles,Maher Albitar	40
11	Early-onset GH deficiency results in spatial memory impairment in mid-life and is prevented by GH supplementation 2009 ·Journal of Endocrinology ·(unknown),William E. Sonntag,Ana Wilson,Amber C. Donahue,(unknown),J.K. Brunso-Bechtold,Michelle M. Nicolle	55
12	Proteomics-based prediction of clinical response in acute myeloid leukemia 2009 ·Experimental Hematology ·Maher Albitar,Steven J. Potts,Francis J. Giles,Susan O’Brien,Iman Jilani,Amber C. Donahue,Elihu H. Estey,Hagop M. Kantarjian	11
13	Detection of nucleophosmin gene mutations in plasma from patients with acute myeloid leukemia: Clinical significance and implications 2009 ·Cancer Biomarkers ·Wanlong Ma,Hagop M. Kantarjian,Xi Zhang,Iman Jilani,Mohammad Sheikholeslami,Amber C. Donahue,Farhad Ravandi,Elihu H. Estey,Susan O’Brien,Michael J. Keating,Francis J. Giles,Maher Albitar	12
14	Measuring Phosphorylated Akt and Other Phosphoinositide 3-kinase-Regulated Phosphoproteins in Primary Lymphocytes 2007 ·Methods in enzymology on CD-ROM/Methods in enzymology ·Amber C. Donahue,Michael G. Kharas,(unknown)	14
15	Distinct signaling mechanisms activate the target of rapamycin in response to different B‐cell stimuli 2007 ·European Journal of Immunology ·Amber C. Donahue,David A. Fruman	62
16	Altered splenic B cell subset development in mice lacking phosphoinositide 3-kinase p85 2004 ·International Immunology ·Amber C. Donahue	27
17	PI3K signaling controls cell fate at many points in B lymphocyte development and activation 2004 ·Seminars in Cell and Developmental Biology ·Amber C. Donahue,(unknown)	52
18	Frontline: The p85α isoform of phosphoinositide 3‐kinase is essential for a subset of B cell receptor‐initiated signaling responses 2004 ·European Journal of Immunology ·Kristen L. Hess,Amber C. Donahue,Kwan Ng,Travis I. Moore,Jean Oak,(unknown)	17
19	Proliferation and Survival of Activated B Cells Requires Sustained Antigen Receptor Engagement and Phosphoinositide 3-Kinase Activation 2003 ·The Journal of Immunology ·Amber C. Donahue,(unknown)	80
20	Jaw involvement in American Burkitt's lymphoma 1984 ·Cancer ·Eric Sariban,Amber C. Donahue,Ian Magrath	56

About Amber C. Donahue

Amber C. Donahue is a scholar working on Genetics, Hematology and Immunology, having authored 22 papers that have together received 583 indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (8 papers), Acute Myeloid Leukemia Research (5 papers) and PI3K/AKT/mTOR signaling in cancer (4 papers). The work is most often cited by research in Genetics (122 citations), Immunology (215 citations) and Hematology (92 citations). Amber C. Donahue has collaborated with scholars based in United States, United Kingdom and Japan. Frequent co-authors include David A. Fruman, Ian Magrath, Eric Sariban, Chen-Hsiung Yeh, Jay G. Wohlgemuth, Gregory Z. Ferl, Owen N. Witte, Anne B. Satterthwaite, Maher Albitar and J.K. Brunso-Bechtold. Their work appears in journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and The Journal of Immunology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact